Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Adaptimmune Therapeutics Plc
ADAPCurrent price
1.39 USD
+0.09 USD (+6.92%)
Last closed
1.3 USD
Company
www.adaptimmune.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
307 952 224 USD
Yield for 12 month
+59.77 %
1Y
3Y
5Y
10Y
15Y
ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2.02 USDP/E ratio
–Dividend Yield
–Current Year
+60 514 653 USD
Last Year
+27 148 000 USD
Current Quarter
+5 678 000 USD
Last Quarter
+233 009 USD
Current Year
+50 657 594 USD
Last Year
-100 578 000 USD
Current Quarter
+2 849 616 USD
Last Quarter
-2 641 783 USD
Key Figures ADAP
1 year
3 years
5 years
10 years
EBITDA
-183 906 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-44.57 %
PEG Ratio
0.11
Return On Equity TTM
-301.91 %
Wall Street Target Price
2.02 USD
Revenue TTM
18 358 000 USD
Book Value
0.095 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-88.1 %
Dividend Yield
–
Gross Profit TTM
-100 578 000 USD
Earnings per share
-0.73 USD
Diluted Eps TTM
-0.73 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ADAP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ADAP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
30.03.2018
Stock Valuation ADAP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
2.8989
Price Sales TTM
4.9178
Enterprise Value EBITDA
-1.3631
Price Book MRQ
7.5026
Financials ADAP
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ADAP
For 52 weeks
0.42 USD
2.05 USD
50 Day MA
1.07 USD
Shares Short Prior Month
4 903 957
200 Day MA
0.98 USD
Short Ratio
2.49
Shares Short
5 641 870
Short Percent
3.31 %
BeatStart